Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-070325
Filing Date
2025-05-13
Accepted
2025-05-13 16:08:40
Documents
67
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q kytx-20250331.htm   iXBRL 10-Q 2356630
2 EX-31.1 kytx-ex31_1.htm EX-31.1 17954
3 EX-31.2 kytx-ex31_2.htm EX-31.2 17942
4 EX-32.1 kytx-ex32_1.htm EX-32.1 11991
5 EX-32.2 kytx-ex32_2.htm EX-32.2 11514
  Complete submission text file 0000950170-25-070325.txt   8392408

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kytx-20250331.xsd EX-101.SCH 1115784
70 EXTRACTED XBRL INSTANCE DOCUMENT kytx-20250331_htm.xml XML 1286912
Mailing Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608
Business Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608 5106268331
Kyverna Therapeutics, Inc. (Filer) CIK: 0001994702 (see all company filings)

EIN.: 831365441 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41947 | Film No.: 25940074
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)